Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072819 | 1.00 | CTSK (0.49) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL3604134 | 0.88 | CTSK (0.49) | CTSKCTSSCAPN1MEN1GAA | |
| SCHEMBL27611196 | 0.88 | CTSK (0.49) | CTSKCTSSCAPN1MEN1GAA | |
| SCHEMBL24145466 | 0.88 | CTSK (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL23797253 | 0.88 | CTSK (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL8314406 | 0.88 | HDAC4 (0.46) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL19668435 | 0.87 | CTSK (0.49) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL31072330 | 0.87 | CTSK (0.49) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL4409723 | 0.87 | CTSK (0.49) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL6745774 | 0.87 | CTSK (0.56) | CTSKCTSSHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3876928-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3876928-A2 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-2882724-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | IRBM - SCIENCE PARK S P A (IT) | 2017-11-01 | — | — | EP | disclosed |
| US-9371295-B2 | Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC | IRBM-SCIENCE PARK S.P.A. (IT) | 2016-06-21 | — | — | US | disclosed |
| US-20150218112-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-08-06 | — | — | US | disclosed |
| EP-2882724-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | IRBM - Science Park S.p.A. (IT) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023754-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | IRBM - SCIENCE PARK S.P.A. (IT) | 2014-02-13 | — | — | WO | disclosed |
| CN-101115742-B | Heterocycle derivatives as histone deacetylase (hdac) inhibitors | ANGELETTI P IST RICHERCHE BIO | 2011-06-22 | — | — | CN | disclosed |
| CN-101115742-A | Heterocycle derivatives as histone deacetylase (hdac) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2008-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC3 | CTSK 987/4885CTSS 442/4885HDAC4 8/4885 |
| US-20150218112-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | HDAC5, HDAC4, HDAC6 | CTSK 2302/4885CTSS 1915/4885HDAC4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.